Revised SPCs: Diflucan (fluconazole) preparations

SPC now notes moderate inhibitors of CYP3A4, such as fluconazole, increase plasma ibrutinib concentrations and may increase risk of toxicity. If the combination cannot be avoided, the dose of ibrutinib should be reduced for the duration of the inhibitor use.

Source:

electronic Medicines compendium